Cargando…
Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing
BACKGROUND: Pseudomonas aeruginosa is a persistent and difficult-to-treat pathogen in many patients, especially those with Cystic Fibrosis (CF). Herein, we describe a longitudinal analysis of a series of multidrug resistant (MDR) P. aeruginosa isolates recovered in a 17-month period, from a young fe...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970513/ https://www.ncbi.nlm.nih.gov/pubmed/35358221 http://dx.doi.org/10.1371/journal.pone.0265129 |
_version_ | 1784679473339170816 |
---|---|
author | Rojas, Laura J. Yasmin, Mohamad Benjamino, Jacquelynn Marshall, Steven M. DeRonde, Kailynn J. Krishnan, Nikhil P. Perez, Federico Colin, Andrew A. Cardenas, Monica Martinez, Octavio Pérez-Cardona, Armando Rhoads, Daniel D. Jacobs, Michael R. LiPuma, John J. Konstan, Michael W. Vila, Alejandro J. Smania, Andrea Mack, Andrew R. Scott, Jacob G. Adams, Mark D. Abbo, Lilian M. Bonomo, Robert A. |
author_facet | Rojas, Laura J. Yasmin, Mohamad Benjamino, Jacquelynn Marshall, Steven M. DeRonde, Kailynn J. Krishnan, Nikhil P. Perez, Federico Colin, Andrew A. Cardenas, Monica Martinez, Octavio Pérez-Cardona, Armando Rhoads, Daniel D. Jacobs, Michael R. LiPuma, John J. Konstan, Michael W. Vila, Alejandro J. Smania, Andrea Mack, Andrew R. Scott, Jacob G. Adams, Mark D. Abbo, Lilian M. Bonomo, Robert A. |
author_sort | Rojas, Laura J. |
collection | PubMed |
description | BACKGROUND: Pseudomonas aeruginosa is a persistent and difficult-to-treat pathogen in many patients, especially those with Cystic Fibrosis (CF). Herein, we describe a longitudinal analysis of a series of multidrug resistant (MDR) P. aeruginosa isolates recovered in a 17-month period, from a young female CF patient who underwent double lung transplantation. Our goal was to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence evolution over time. METHODS: Twenty-two sequential P. aeruginosa isolates were obtained within a 17-month period, before and after a double-lung transplant. At the end of the study period, antimicrobial susceptibility testing, whole genome sequencing (WGS), phylogenetic analyses and RNAseq were performed in order to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence changes over time. RESULTS: The majority of isolates were resistant to almost all tested antibiotics. A phylogenetic reconstruction revealed 3 major clades representing a genotypically and phenotypically heterogeneous population. The pattern of mutation accumulation and variation of gene expression suggested that a group of closely related strains was present in the patient prior to transplantation and continued to change throughout the course of treatment. A trend toward accumulation of mutations over time was observed. Different mutations in the DNA mismatch repair gene mutL consistent with a hypermutator phenotype were observed in two clades. RNAseq performed on 12 representative isolates revealed substantial differences in the expression of genes associated with antibiotic resistance and virulence traits. CONCLUSIONS: The overwhelming current practice in the clinical laboratories setting relies on obtaining a pure culture and reporting the antibiogram from a few isolated colonies to inform therapy decisions. Our analyses revealed significant underlying genomic heterogeneity and unpredictable evolutionary patterns that were independent of prior antibiotic treatment, highlighting the need for comprehensive sampling and population-level analysis when gathering microbiological data in the context of CF P. aeruginosa chronic infection. Our findings challenge the applicability of antimicrobial stewardship programs based on single-isolate resistance profiles for the selection of antibiotic regimens in chronic infections such as CF. |
format | Online Article Text |
id | pubmed-8970513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-89705132022-04-01 Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing Rojas, Laura J. Yasmin, Mohamad Benjamino, Jacquelynn Marshall, Steven M. DeRonde, Kailynn J. Krishnan, Nikhil P. Perez, Federico Colin, Andrew A. Cardenas, Monica Martinez, Octavio Pérez-Cardona, Armando Rhoads, Daniel D. Jacobs, Michael R. LiPuma, John J. Konstan, Michael W. Vila, Alejandro J. Smania, Andrea Mack, Andrew R. Scott, Jacob G. Adams, Mark D. Abbo, Lilian M. Bonomo, Robert A. PLoS One Research Article BACKGROUND: Pseudomonas aeruginosa is a persistent and difficult-to-treat pathogen in many patients, especially those with Cystic Fibrosis (CF). Herein, we describe a longitudinal analysis of a series of multidrug resistant (MDR) P. aeruginosa isolates recovered in a 17-month period, from a young female CF patient who underwent double lung transplantation. Our goal was to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence evolution over time. METHODS: Twenty-two sequential P. aeruginosa isolates were obtained within a 17-month period, before and after a double-lung transplant. At the end of the study period, antimicrobial susceptibility testing, whole genome sequencing (WGS), phylogenetic analyses and RNAseq were performed in order to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence changes over time. RESULTS: The majority of isolates were resistant to almost all tested antibiotics. A phylogenetic reconstruction revealed 3 major clades representing a genotypically and phenotypically heterogeneous population. The pattern of mutation accumulation and variation of gene expression suggested that a group of closely related strains was present in the patient prior to transplantation and continued to change throughout the course of treatment. A trend toward accumulation of mutations over time was observed. Different mutations in the DNA mismatch repair gene mutL consistent with a hypermutator phenotype were observed in two clades. RNAseq performed on 12 representative isolates revealed substantial differences in the expression of genes associated with antibiotic resistance and virulence traits. CONCLUSIONS: The overwhelming current practice in the clinical laboratories setting relies on obtaining a pure culture and reporting the antibiogram from a few isolated colonies to inform therapy decisions. Our analyses revealed significant underlying genomic heterogeneity and unpredictable evolutionary patterns that were independent of prior antibiotic treatment, highlighting the need for comprehensive sampling and population-level analysis when gathering microbiological data in the context of CF P. aeruginosa chronic infection. Our findings challenge the applicability of antimicrobial stewardship programs based on single-isolate resistance profiles for the selection of antibiotic regimens in chronic infections such as CF. Public Library of Science 2022-03-31 /pmc/articles/PMC8970513/ /pubmed/35358221 http://dx.doi.org/10.1371/journal.pone.0265129 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Rojas, Laura J. Yasmin, Mohamad Benjamino, Jacquelynn Marshall, Steven M. DeRonde, Kailynn J. Krishnan, Nikhil P. Perez, Federico Colin, Andrew A. Cardenas, Monica Martinez, Octavio Pérez-Cardona, Armando Rhoads, Daniel D. Jacobs, Michael R. LiPuma, John J. Konstan, Michael W. Vila, Alejandro J. Smania, Andrea Mack, Andrew R. Scott, Jacob G. Adams, Mark D. Abbo, Lilian M. Bonomo, Robert A. Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing |
title | Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing |
title_full | Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing |
title_fullStr | Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing |
title_full_unstemmed | Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing |
title_short | Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing |
title_sort | genomic heterogeneity underlies multidrug resistance in pseudomonas aeruginosa: a population-level analysis beyond susceptibility testing |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970513/ https://www.ncbi.nlm.nih.gov/pubmed/35358221 http://dx.doi.org/10.1371/journal.pone.0265129 |
work_keys_str_mv | AT rojaslauraj genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT yasminmohamad genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT benjaminojacquelynn genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT marshallstevenm genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT derondekailynnj genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT krishnannikhilp genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT perezfederico genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT colinandrewa genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT cardenasmonica genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT martinezoctavio genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT perezcardonaarmando genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT rhoadsdanield genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT jacobsmichaelr genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT lipumajohnj genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT konstanmichaelw genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT vilaalejandroj genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT smaniaandrea genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT mackandrewr genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT scottjacobg genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT adamsmarkd genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT abbolilianm genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting AT bonomoroberta genomicheterogeneityunderliesmultidrugresistanceinpseudomonasaeruginosaapopulationlevelanalysisbeyondsusceptibilitytesting |